Skip to main content
Log in

Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics

  • Research Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

A RP-LC method was developed and validated for simultaneous determination of the active components, azilsartan medoxomil (AZL) and chlorthalidone (CLT), in their novel antihypertensive combined recipe. The chromatographic separation was achieved on an Eclipse XDB-C18 (4.6 × 150 mm, 5 μm) column using a mobile phase consisting of methanol/potassium hydrogen phosphate buffer (pH 8, 0.05 M) (40:60, v/v) in isocratic mode. The flow rate was maintained at 0.8 mL min−1 at ambient temperature. Detection was carried out at 210 nm. The method was validated according to the ICH guidelines. Linearity, accuracy, and precision were satisfactory over the concentration range of 5.0–50.0 and 2.5–25.0 μg mL−1 for AZL and CLT, respectively (r 2 = 0.9999). LODs for AZL and CLT were 0.90 and 0.32 μg mL−1, whereas LOQs were 2.72 and 0.98 μg mL−1, respectively. Both drugs were subjected to forced degradation studies under hydrolysis (neutral, acidic, and alkaline), oxidative, and photolytic extensive stress conditions. The proposed method is stability indicating by the resolution of the investigated drugs from their degradation products. Moreover, the kinetics of the acidic degradation of AZL as well as the kinetics of the alkaline degradation of CLT were investigated. Arrhenius plots were constructed and the apparent first-order rate constants, half-life times, shelf-life times, and the activation energies of the degradation processes were calculated. The method was successfully applied for the determination of the studied drugs simultaneously in their coformulated tablet. The developed method is specific and stability indicating for the quality control and routine analysis of the cited medications in their pharmaceutical preparations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Scheme 1
Scheme 2
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Baker WL, White WB (2011) Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension. Ann Pharmacother 45:1506–1515. doi:10.1345/aph.1Q468

    Article  CAS  Google Scholar 

  2. Kurtz TW, Kajiya T (2012) Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 8:133–143

    Article  Google Scholar 

  3. Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, Sakamoto H, Kuroita T, Kawaguchi N, Nishigaki N, Nagaya H (2011) Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 669:84–93

    Article  CAS  Google Scholar 

  4. Vekariya PP, Joshi HS (2013) Development and validation of RP-HPLC method for azilsartan medoxomil potassium quantitation in human plasma by solid phase extraction procedure. ISRN Spectrosc 2013:6. doi:10.1155/2013/572170

    Article  Google Scholar 

  5. Sweetman S (2009) Martindale: the complete drug reference, 36th edn. The Pharmaceutical Press, London

    Google Scholar 

  6. Singh B, Patel DK, Ghosh SK (2009) A reversed-phase high performance liquid chromatographic method for determination of chlorthalidone in pharmaceutical formulation. Int J Pharm Sci 1:24–29

    CAS  Google Scholar 

  7. Mhaske RA, Sahasrabudhe S, Mhaske AA, Garole DJ (2012) RP-HPLC method for simultataneous determination of atorvastatin calcium, olmesartan medoxomil, candesartan, hydrochlorothiazide and chlorthalidone - application to commercially available drug products. Int J Pharm Sci Res 3:793–801

    CAS  Google Scholar 

  8. Woo H, Kim JW, Han KM, Lee JH, Hwang IS, Kim J, Kweon SJ, Cho S, Chae KR, Han SY (2013) Simultaneous analysis of 17 diuretics in dietary supplements by HPLC and LC-MS/MS. Food Addit Contam, Part A 30:209–217. doi:10.1080/19440049.2012.738939

    Article  CAS  Google Scholar 

  9. Youssef RM, Maher HM, El-Kimary EI, Hassan EM, Barary MH (2013) Validated stability-indicating methods for the simultaneous determination of amiloride hydrochloride, atenolol, and chlorthalidone using HPTLC and HPLC with photodiode array detector. J AOAC Int 96:313–323. doi:10.5740/jaoacint.11-347

    Article  CAS  Google Scholar 

  10. Salem H (2004) High-performance thin-layer chromatography for the determination of certain antihypertensive mixtures. Sci Pharm 72:157–174

    CAS  Google Scholar 

  11. Ciborowski M, Icardo MC, Mateo JV, Martinez Calatayud J (2004) FI-chemiluminometric study of thiazides by on-line photochemical reaction. J Pharm Biomed Anal 36:693–700. doi:10.1016/j.jpba.2004.08.020

    Article  CAS  Google Scholar 

  12. Parmar KE, Mehta RS (2013) First order derivative spectrophotometric method for simultaneous estimation of telmisartan and chlorthalidone in bulk and pharmaceutical dosage form. Int Res J Pharm 4:224–228. doi:10.7897/2230-8407.04348

    Article  Google Scholar 

  13. Lu M, Li X, Feng Q, Chen G, Zhang L (2010) Analysis of diuretics by capillary electrochromatography using poly(1-hexadecene-co-TMPTMA) monolithic column. Sepu 28:253–259. doi:10.3724/sp.j.1123.2010.00253

    CAS  Google Scholar 

  14. Cheng JWM (2013) Azilsartan/chlorthalidone combination therapy for blood pressure control. Integr Blood Press Control 6:39–48. doi:10.2147/ibpc.s34792

    Article  CAS  Google Scholar 

  15. Kasimala MB, Kasimala BB (2012) Reverse phase-HPLC method development and validation for the simultaneous estimation of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms. Jamonline 2:117–126

    Google Scholar 

  16. ICH (1996) International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline Q1A(R2) and (Q1B), Stability testing of new drug substances and products, 2003 and stability testing: photostability testing of new drug substances and products. ICH: Geneva, Switzerland

  17. ICH (2013) Harmonized tripartite guideline, validation of analytical procedures: text and methodology, Q2(R1), current step 4 version, parent guidelines on methodology. Dated November 6 1996, Incorporated in November 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed April 23

  18. Sinko PJ (2011) Martin’s physical pharmacy and pharmaceutical sciences: physical chemical and biopharmaceutical principles in the pharmaceutical sciences. 6th ed. Lippincott, Philadelphia, PA

Download references

Acknowledgments

We gratefully acknowledge the financial support received from Cultural Affairs and Mission Sector (Egyptian Government) for Joint Supervision mission (JS 2756).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Walid M. Ebeid.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

PDF 1.64 mb

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ebeid, W.M., Elkady, E.F., El-Zaher, A.A. et al. Stability-indicating RP-LC method for determination of azilsartan medoxomil and chlorthalidone in pharmaceutical dosage forms: application to degradation kinetics. Anal Bioanal Chem 406, 6701–6712 (2014). https://doi.org/10.1007/s00216-014-8085-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-014-8085-0

Keywords

Navigation